Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 5/20 | 0.46 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 13/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 10/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.41 |
| ▸ | MASP2 | O00187 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3155052 | 0.83 | F2 (0.53) | KLKB1F2PRSS1PRSS2PRSS3 | |
| SCHEMBL3144880 | 0.81 | F2 (0.50) | KLKB1F2PRSS1PRSS2PRSS3 | |
| SCHEMBL3141272 | 0.79 | F10 (0.43) | KLKB1F2PRSS1MASP2 | |
| SCHEMBL3149500 | 0.77 | F2 (0.39) | F2 | |
| SCHEMBL3157959 | 0.74 | MLYCD (0.43) | F2MASP2 | |
| SCHEMBL3153760 | 0.73 | F2 (0.52) | KLKB1F2PRSS1PRSS2PRSS3 | |
| SCHEMBL3149587 | 0.71 | SLC6A2 (0.41) | F2 | |
| SCHEMBL3140039 | 0.71 | MAOB (0.35) | KLKB1MAP4K1F2PRSS1PRSS2 | |
| SCHEMBL17442649 | 0.70 | KLKB1 (0.57) | KLKB1F2PRSS1PRSS2PRSS3 | |
| SCHEMBL23279842 | 0.69 | F2 (0.53) | KLKB1F2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | CHRM1, ARG1, ARG2 | KLKB1 3491/4885MAP4K1 1576/4885F2 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.